title: Clinical usefulness in geriatric patients of combining CHADS2 and HEMORR2HAGES scores to guide antithrombotic prophylaxis in atrial fibrillation.
abstract: OBJECTIVE
  Two scores exist to assess the benefits and risks of antithrombotic therapy in patients with atrial fibrillation: CHADS2 [for Congestive heart failure, Hypertension, Age over 75, Diabetes mellitus; and 2 points for a history of Stroke] and HEMORR2HAGES [for Hepatic or renal failure, Ethanol abuse, Malignancy, Older (age over 75), Reduced platelet count or function, 2 points for Rebleeding risk Hypertension (uncontrolled), Anemia, Genetic factors, Excessive fall risk (including neurodegenerative and psychiatric disorders) and history of Stroke]. The potential value of using both scores routinely was studied in order to guide the choice of antithrombotic therapy for geriatric patients.
  
  
  METHODS
  Retrospective calculation of CHADS2 and HEMORR2HAGES scores and discharge treatment were collected for all patients with atrial fibrillation during a six-month period. All files were analysed when there were differences between therapeutic choices and the results of analysis of combining the two scores.
  
  
  RESULTS
  83 patients were identified. Their mean age was 89.2±4.9 years and 30% of them were on oral anticoagulants on discharge. Usual prescription habits of oral anticoagulants correlated strongly with each of the scores and with the difference between the two scores. The clinical usefulness of using the two scores seemed poor since they indicated that two-thirds of the patients had a similar risk of hemorrhagic and ischemic events.
  
  
  CONCLUSIONS
  Based on this preliminary study, the CHADS2 and HEMORR2HAGES scores are associated with the prescription of oral anticoagulants, but their routine use may not significantly change the choice of antithrombotic therapy for patients with atrial fibrillation.
authors.affiliation: Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Gériatrie, 75908 Paris Cedex 15, France. dominique.somme@egp.aphp.fr
authors.forename: Dominique
authors.initials: D
authors.lastname: Somme
authors.forename: Aline
authors.initials: A
authors.lastname: Corvol
authors.forename: Céline
authors.initials: C
authors.lastname: Lazarovici
authors.forename: Hayat
authors.initials: H
authors.lastname: Lahjibi-Paulet
authors.forename: Mathilde
authors.initials: M
authors.lastname: Gisselbrecht
authors.forename: Olivier
authors.initials: O
authors.lastname: Saint-Jean
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy*; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D012307:Risk Factors; D013927:Thrombosis / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents